このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Grand Pharmaceutical Group バランスシートの健全性
財務の健全性 基準チェック /66
Grand Pharmaceutical Groupの総株主資本はHK$15.3B 、総負債はHK$3.3Bで、負債比率は21.7%となります。総資産と総負債はそれぞれHK$22.5BとHK$7.2Bです。 Grand Pharmaceutical Groupの EBIT はHK$2.9Bで、利息カバレッジ比率14.5です。現金および短期投資はHK$3.3Bです。
主要情報
21.7%
負債資本比率
HK$3.31b
負債
| インタレスト・カバレッジ・レシオ | 14.5x |
| 現金 | HK$3.32b |
| エクイティ | HK$15.27b |
| 負債合計 | HK$7.24b |
| 総資産 | HK$22.52b |
財務の健全性に関する最新情報
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Recent updates
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt
Apr 26Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)
Apr 08Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching
Mar 24If You Had Bought China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Shares Five Years Ago You'd Have Earned 332% Returns
Mar 11財務状況分析
短期負債: 512の 短期資産 ( HK$7.0B ) が 短期負債 ( HK$5.7B ) を超えています。
長期負債: 512の短期資産 ( HK$7.0B ) が 長期負債 ( HK$1.5B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: 512総負債よりも多くの現金を保有しています。
負債の削減: 512の負債対資本比率は、過去 5 年間で34.6%から21.7%に減少しました。
債務返済能力: 512の負債は 営業キャッシュフロー によって 十分にカバー されています ( 73.3% )。
インタレストカバレッジ: 512の負債に対する 利息支払い は EBIT ( 14.5 x coverage) によって 十分にカバーされています。